Sio Gene Therapies Inc.
CIK 0001636050
Revenue (TTM)
—
Q3 Feb 2023
Net Income (TTM)
−$40.96M
+47.7% YoY
Q3 Feb 2023
EPS Diluted (TTM)
−$0.55
+48.6% YoY
Q3 Feb 2023
Gross Margin
—
Q3 Feb 2023
Operating Margin
—
Q3 Feb 2023
Net Margin
—
Q3 Feb 2023
Free Cash Flow (TTM)
—
Q3 Feb 2023
Cash
$46.13M
Q3 Feb 2023
Total Debt
$0
Q3 Feb 2023
Shares Outstanding
73.98M sh
Q3 Feb 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.